In summary, results from the present study suggest that chronic treatment with a potent PPAR-γ agonist may introduce a risk factor for a sequel of events that may precipitate the eventual development of left ventricular dysfunction and CHF even in an otherwise healthy heart. This evidence concerns the gene PPARG and congestive heart failure.